Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725499 | 0.89 | TDP1 (0.44) | TRPV1NPSR1TDP1L3MBTL1GLA | |
| SCHEMBL16021154 | 0.79 | KDM4E (0.46) | TRPV1NPSR1TDP1L3MBTL1GLA | |
| SCHEMBL16019373 | 0.76 | KDM4E (0.44) | TRPV1NPSR1TDP1L3MBTL1GLA | |
| SCHEMBL1476420 | 0.76 | PRKDC (0.47) | TRPV1KDM4EMAPT | |
| SCHEMBL1474722 | 0.76 | TRPV1 (0.41) | TRPV1NPSR1TDP1L3MBTL1GLA | |
| SCHEMBL21725515 | 0.76 | TRPV1 (0.42) | TRPV1L3MBTL1KDM4EHSD17B10MAPT | |
| SCHEMBL3997876 | 0.75 | TRPV1 (0.48) | TRPV1NPSR1TDP1L3MBTL1GLA | |
| SCHEMBL22193262 | 0.75 | TRPV1 (0.48) | TRPV1NPSR1 | |
| SCHEMBL25510874 | 0.74 | HSD17B10 (0.42) | TRPV1TDP1L3MBTL1ATMKDM4E | |
| SCHEMBL4000217 | 0.74 | TRPV1 (0.47) | TRPV1NPSR1TDP1L3MBTL1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | TRPV1 104/4885NPSR1 116/4885TDP1 4384/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | TRPV1 106/4885NPSR1 114/4885TDP1 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.